logo

For the Inventor, By the Inventor

Seville, Spain

Thomas Stief

This inventor holds 7 USPTO granted patents. Top assignee: Behringwerke Aktiengesellschaft. Active years: 1991-1997.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Thomas Stief. Retrieved from https://idiyas.com/inventor/thomas-stief

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 7

% Patents Active = 100.0

Average Co-Inventor Count = 1.8

ph-index = 3

Forward Citations = 22(Granted Patents)


Location History:

  • Marburg, DE (1991 - 1996)
  • Sevilla, ES (1994 - 1997)
  • Seville, ES (1995 - 1997)

Company Filing History:

goldMedal7 out of 340 
 
Behringwerke Aktiengesellschaft
 patents

Years Active: 1991-1997

Loading Chart...
7 patents (USPTO):Explore Patents
1. 5695753 - Transglutaminases as immunosuppressants (1997-12-09),
2. 5607837 - Method for the determination of the plasminogen activator activity in (1997-03-04),
3. 5512449 - Method for the functional determination of protein C inhibitor (1996-04-30),
4. 5464615 - Use of transglutaminases as immunosuppressants (1995-11-07),
5. 5427918 - Fibrin(ogen) derivatives, process for their preparation and their use (1995-06-27),
6. 5376631 - Fibrin(ogen) derivatives, process for their preparation and their use (1994-12-27),
7. 5057414 - Method for the determination of the activity of serine proteases or (1991-10-15),

Title: Biography of Inventor Thomas Stief

Introduction

Thomas Stief is a prominent inventor based in Sevilla, Spain, known for his significant contributions to the field of biochemistry. With a total of 7 patents to his name, he has made remarkable advancements in the development of immunosuppressants and methods for determining plasminogen activator activity.

Latest Patents

Among his latest patents, Stief has developed a process utilizing transglutaminases as immunosuppressants. This innovative approach describes the potential of transglutaminases in creating a pharmaceutical that includes both a transglutaminase and a plasminogen activator inhibitor. Additionally, he has disclosed a method for determining plasminogen activator activity in biological fluids, which effectively addresses the influence of alpha-2-antiplasmin on PA activity determination.

Career Highlights

Stief's career is marked by his work at Behringwerke Aktiengesellschaft, where he has been instrumental in advancing research and development in his field. His expertise in biochemistry has led to groundbreaking inventions that have the potential to impact medical treatments significantly.

Collaborations

Throughout his career, Thomas Stief has collaborated with notable colleagues, including Norbert Heimburger and Hans U Schorlemmer. These partnerships have fostered a collaborative environment that encourages innovation and the sharing of ideas.

Conclusion

In summary,

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…